Autoimmune (37)

FDA Grants DSG3-CAART Orphan Drug Designation for the Treatment of Pemphigus Vulgaris

Cabaletta Bio, Inc announced that the US Food and Drug Administration (FDA) has granted Orphan Drug Designation for the Company’s lead product candidate, DSG3-CAART, for the treatment of pemphigus vulgaris (PV). DSG3-CAART is designed to target the cause of mucosal PV (mPV), B cells that express pathogenic autoantibodies directed against the...